METHODS OF TREATING PANCYTOPENIA
Pancytopenia, in particular lymphopenia is treated with compositions which include an IL-15 superagonist, IL-15, an IL-15 mutant, IL-15:IL-15 receptor alpha (IL-15Rα) complex or combinations thereof. Administration of preferred compositions results in the increase of blood cells, in particular, lymphocytes in subjects in need of such treatment.
1 . A method of treating lymphopenia in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of ALT-803, wherein the subject is undergoing radiation therapy and wherein the ALT-803 is administered within 48 hours of the radiation therapy.
2 - 8 . (canceled)
9 . The method of claim 1 , wherein the radiation therapy is 50 Gray or less over 5 weeks.
10 . The method of claim 1 , wherein the radiation therapy is less than 45 Gray over 5 weeks.
11 . The method of claim 1 , wherein the radiation therapy is less than 40 Gray over 5 weeks.
12 . The method of claim 1 , wherein the radiation therapy is less than 35 Gray over 5 weeks.
13 . The method of claim 1 , wherein the composition comprising a therapeutically effective amount of ALT-803 is administered on the same day as the radiation therapy.
14 . The method of claim 1 , wherein the composition comprising a therapeutically effective amount of ALT-803 is administered within 24 hours of the radiation therapy.
15 . (canceled)
16 . (canceled)
17 . The method of claim 1 , further comprising administering one or more chemotherapeutic agents, cytokine antagonists, cytokine receptor antagonists, cytokines, chemokines, growth factors, hpG-CSF, EPO, lymphopoietin, adoptive cell therapy, anti-viral agents, viral entry receptor antagonists, checkpoint inhibitors, adjuvants, or combinations thereof.
18 . The method of claim 17 , wherein the adoptive cell therapy is administered and comprises administration of lymphocytes, stem cells, or combinations thereof.
19 . The method of claim 17 , wherein the cytokines are administered and comprise T helper 1 (TH1)-inducing cytokines.
20 . The method of claim 17 , wherein the cytokines are administered and comprise T helper 2 (TH2)-inducing cytokines.
21 . The method of claim 19 , wherein the TH1-inducing cytokines comprise interleukin-2 (IL-2), IL-10, IL-12, IL-18, IL-27, tumor necrosis factor-alpha (TNFα), TNFβ, an interferon, or combinations thereof.
22 . The method of claim 20 , wherein the TH2-inducing cytokines comprise IL-4, IL-5, IL-6, IL-9, IL-13, IL-19, IL-25, IL-31, IL-33, an interferon, or combinations thereof.
23 - 40 . (canceled)
41 . A method of treating lymphopenia in a subject in need thereof, the method comprising administering to the subject a composition comprising a therapeutically effective amount of ALT-803, wherein the subject is undergoing oncological chemotherapy and wherein the ALT-803 is administered with 48 hours of the chemotherapy.
42 . The method of claim 41 , wherein the subject is suffering from a disease or disorder associated with chemotherapy-induced lymphopenia.
43 . The method of claim 42 , wherein the composition comprising a therapeutically effective amount of ALT-803 is administered on the same day as the chemotherapy.
44 . The method of claim 42 , wherein the composition comprising a therapeutically effective amount of ALT-803 is administered within 24 hours of the chemotherapy.
45 . The method of claim 41 , further comprising administering one or more chemotherapeutic agents, cytokine antagonists, cytokine receptor antagonists, cytokines, chemokines, growth factors, hpG-CSF, EPO, lymphopoietin, adoptive cell therapy, anti-viral agents, viral entry receptor antagonists, checkpoint inhibitors, adjuvants, or combinations thereof.
46 . The method of claim 45 , wherein the adoptive cell therapy is administered and comprises administration of lymphocytes, stem cells, or combinations thereof.
47 . The method of claim 45 , wherein the cytokines are administered and comprise T helper 1 (T H 1)-inducing cytokines.
48 . The method of claim 45 , wherein the cytokines are administered and comprise T helper 2 (T H 2)-inducing cytokines.
49 . The method of claim 47 , wherein the TH1-inducing cytokines comprise interleukin-2 (IL-2), IL-10, IL-12, IL-18, IL-27, tumor necrosis factor-alpha (TNFα), TNFβ, an interferon, or combinations thereof.
50 . The method of claim 48 , wherein the T H 2-inducing cytokines comprise IL-4, IL-5, IL-6, IL-9, IL-13, IL-19, IL-25, IL-31, IL-33, an interferon, or combinations thereof.
51 . The method of claim 1 , wherein the therapeutically effective amount of ALT-803 is between about 0.1 μg/kg and about 100 mg/kg body weight.
52 . The method of claim 41 , wherein the therapeutically effective amount of ALT-803 is between about 0.1 μg/kg and about 100 mg/kg body weight.